-
Corcept Therapeutics Is 'Fairly Valued,' Stifel Says In Downgrade
Thursday, May 31, 2018 - 12:52pm | 381Read More...Stifel's bullish case for Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company that focuses on drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, no longer applies. The Analyst Stifel's Adam Walsh downgraded...
-
Goldman Sachs On Specialty Pharma: Buy Catalent, Sell Valeant
Wednesday, January 24, 2018 - 12:27pm | 678Read More...Investors are hard pressed to find a standout in the specialty pharmaceutical space as many companies lack the "positive narrative" that can be found the rest of the biopharmaceutical space, analysts at Goldman Sachs said in an industry-wide report. The Analyst Goldman Sachs' Dana...
